12 Month Data Release Pres - Q& A, page-5

That is a superb and comprehensive summary of the Q&A session Mozz. This should be bookmarked by all holders as the referral template for the coming 6-18 months.

On the session itself, i’m not sure if PAR have ever previously released a preso with such a positive and focused plan going forward - especially when talking about imminent monetisation of product. It feels a little bit like the start of a new chapter for the team. The commercialisation era. The confidence was palpable, and they even seemed…..relaxed, as if they know what is coming.

I’ve voiced a little bit of doubt on this forum about a China deal because i’ve been burned in a sort-of similar situation before (once bitten, twice shy) but people should just ignore me. When you see it all laid out like this, I feel very confident that all the deals will come in time. I hope they come in a manner which offsets the need for dilution as that would be profound for our market cap I feel. To read that a China OA deal would cover funding for all Phase III trials (I missed that first time round) and that these 12-month data - and no doubt MRIs which are apparently set to ‘surprise the market’ within weeks - are a godsend to these potential partnership discussions in China, it really brings it home that we are entering into a period very shortly with PAR where one single announcement could drop and change everything.

Thanks again for the write-up. I will be revisiting to read your OP time and again in the weeks/months ahead.